Who owns the QUAISAR DRUG DESIGN PLATFORM trademark?

The QUAISAR DRUG DESIGN PLATFORM trademark is owned by PSIVANT THERAPEUTICS, INC..

What class is the QUAISAR DRUG DESIGN PLATFORM trademark registered in?

The QUAISAR DRUG DESIGN PLATFORM trademark is registered in Class 009 (Electronics, software & scientific instruments), Class 042 (Scientific, technology & SaaS services).

What is the serial number for QUAISAR DRUG DESIGN PLATFORM?

The USPTO serial number for QUAISAR DRUG DESIGN PLATFORM is 97760513.

What is the registration number for QUAISAR DRUG DESIGN PLATFORM?

QUAISAR DRUG DESIGN PLATFORM is registered under USPTO registration number 7963432.

QUA

USPTO Trademark Record

REGISTERED

QUAISAR DRUG DESIGN PLATFORM

SN 97760513·Reg 7963432·Filed Jan 19, 2023

Owner PSIVANT THERAPEUTICS, INC.

Scientific, research, navigation, surveying, photographic, cinematographic, audiovisual, optical, weighing, measuring, signalling, detecting, testing, inspecting, life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling the distribution or use of electricity; apparatus and instruments for recording, transmitting, reproducing or processing sound, images or data; recorded and downloadable multimedia files, computer software, blank digital or analogue recording and storage media; mechanisms for coin-operated apparatus; cash registers, calculating devices; computers and computer peripheral devices; diving suits, divers' masks, ear plugs for divers, nose clips for divers, gloves for divers, breathing apparatus for underwater swimming; fire-extinguishing apparatus.; Scientific and technological services and research and design relating thereto; industrial analysis, industrial research and industrial design services; quality control and authentication services; design and development of computer hardware and software.

QUAISAR DRUG DESIGN PLATFORM (Serial No. 97760513), Registration No. 7963432, is a registered US trademark filed on Jan 19, 2023 by PSIVANT THERAPEUTICS, INC.. This trademark covers Class 009 (Electronics, software & scientific instruments), Class 042 (Scientific, technology & SaaS services).

early section 8: September 30, 2031

Mark Intelligence

QUAISAR DRUG DESIGN PLATFORM (Reg. #7963432) is a registered US trademark that has been protecting its owner, PSIVANT THERAPEUTICS, INC., since 2023. The mark covers Class 009 (Electronics, software & scientific instruments) and Class 042 (Scientific, technology & SaaS services) respectively. Goods and services include Scientific, research, navigation, surveying, photographic, cinematographic, audiovisual, optical, weighing, measuring, s.... The mark faced 1 opposition proceeding during prosecution.

FILED

Jan 19, 2023

SERIAL

97760513

REG#

7963432

REGISTERED

Sep 30, 2025

Owner

Applicant

PSIVANT THERAPEUTICS, INC.

Entity

Corporation

State

Address

451 D STREET, BOSTON, MA, 02210

Country

Attorney

NameJoyce M. Ferraro

Law firm

Joyce M. Ferraro FROSS ZELNICK LEHRMAN & ZISSU, P.C.

Docket

ROIV 2301733

Address

151 WEST 42ND STREET, 17TH FLOOR, NEW YORK, NY 10036, United States

Get pre-filing clearance

AI attorney analyzes your proposed mark against USPTO — Go/No-Go verdict, class-by-class risks, and strategy recommendations.

Run clearance

Filing Information

StatusREGISTERED

Filing DateJan 19, 2023

Serial Number97760513

Registration No.7963432

Registration DateSep 30, 2025

Status DateSep 30, 2025

Published for OppositionAug 12, 2025

Mark TypeStandard characters

Attorney DocketROIV 2301733

Status DescriptionLive and registered

Filing Signals

FILED

2023

YEARS AGO

CLASSES

MADRID FILINGS

—

Opposed 1× during prosecution

Search 15M+ trademarks

Free USPTO lookups by name, owner, or serial number. No account needed.

Search now

Full Goods & Services

CLASSES

OFFICE

USPTO

COUNTRY

Class 009Electronics, software & scientific instruments

US codes: 021, 023, 026, 036, 038

Class 042Scientific, technology & SaaS services

US codes: 100, 101

Scientific and technological services and research and design relating thereto; industrial analysis, industrial research and industrial design services; quality control and authentication services; design and development of computer hardware and software.

This description is as filed with the USPTO and defines the scope of trademark protection.

Status History

35 events

REGISTERED-PRINCIPAL REGISTER

Sep 30, 2025

REGISTERED-PRINCIPAL REGISTER

NOTICE OF REGISTRATION CONFIRMATION EMAILED

Sep 30, 2025

NOTICE OF REGISTRATION CONFIRMATION EMAILED

PUBLISHED FOR OPPOSITION

Aug 12, 2025

PUBLISHED FOR OPPOSITION

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Aug 12, 2025

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Aug 06, 2025

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED

Jul 18, 2025

ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED

EXAMINERS AMENDMENT -WRITTEN

Jun 26, 2025

EXAMINERS AMENDMENT -WRITTEN

EXAMINERS AMENDMENT E-MAILED

Jun 26, 2025

EXAMINERS AMENDMENT E-MAILED

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

Jun 26, 2025

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

EXAMINER'S AMENDMENT ENTERED

Jun 26, 2025

EXAMINER'S AMENDMENT ENTERED

APPROVED FOR PUB - PRINCIPAL REGISTER

Jun 26, 2025

APPROVED FOR PUB - PRINCIPAL REGISTER

ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED

Mar 11, 2025

ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED

ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED

Mar 11, 2025

ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED

NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED

Mar 11, 2025

NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED

TEAS REQUEST FOR RECONSIDERATION RECEIVED

Dec 16, 2024

TEAS REQUEST FOR RECONSIDERATION RECEIVED

CORRESPONDENCE RECEIVED IN LAW OFFICE

Dec 16, 2024

CORRESPONDENCE RECEIVED IN LAW OFFICE

TEAS/EMAIL CORRESPONDENCE ENTERED

Dec 16, 2024

TEAS/EMAIL CORRESPONDENCE ENTERED

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

Sep 12, 2024

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

Sep 12, 2024

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

FINAL REFUSAL WRITTEN

Jun 15, 2024

FINAL REFUSAL WRITTEN

FINAL REFUSAL E-MAILED

Jun 15, 2024

FINAL REFUSAL E-MAILED

NOTIFICATION OF FINAL REFUSAL EMAILED

Jun 15, 2024

NOTIFICATION OF FINAL REFUSAL EMAILED

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

Apr 03, 2024

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

TEAS/EMAIL CORRESPONDENCE ENTERED

Jan 18, 2024

TEAS/EMAIL CORRESPONDENCE ENTERED

TEAS RESPONSE TO OFFICE ACTION RECEIVED

Jan 17, 2024

TEAS RESPONSE TO OFFICE ACTION RECEIVED

CORRESPONDENCE RECEIVED IN LAW OFFICE

Jan 17, 2024

CORRESPONDENCE RECEIVED IN LAW OFFICE

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

Oct 16, 2023

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

Oct 16, 2023

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

Oct 04, 2023

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

NON-FINAL ACTION WRITTEN

Jul 17, 2023

NON-FINAL ACTION WRITTEN

NON-FINAL ACTION E-MAILED

Jul 17, 2023

NON-FINAL ACTION E-MAILED

NOTIFICATION OF NON-FINAL ACTION E-MAILED

Jul 17, 2023

NOTIFICATION OF NON-FINAL ACTION E-MAILED

ASSIGNED TO EXAMINER

May 31, 2023

ASSIGNED TO EXAMINER

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Feb 08, 2023

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

NEW APPLICATION ENTERED

Jan 23, 2023

NEW APPLICATION ENTERED

QUAISAR DRUG DESIGN PLATFORM

Get pre-filing clearance

Search 15M+ trademarks

Run a conflict check

Other Marks by PSIVANT THERAPEUTICS, INC.

Other Marks in Class 009 — Electronics, software & scientific instruments

Other Marks by Joyce M. Ferraro

Resources

Company